TBPH Theravance Biopharma Inc
Price (delayed)
$9.272
Market cap
$458.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.15
Enterprise value
$469.88M
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives
Highlights
TBPH's revenue is up by 12% year-on-year
The gross profit has grown by 12% YoY
TBPH's equity is down by 18% year-on-year and by 5% since the previous quarter
Theravance Biopharma's EPS has decreased by 15% YoY and by 12% QoQ
Key stats
What are the main financial stats of TBPH
Market
Valuations
Earnings
Shares outstanding
49.47M
Market cap
$458.69M
Enterprise value
$469.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.6
Price to sales (P/S)
7.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.3
Revenue
$64.38M
Gross profit
$64.38M
Operating income
-$46.95M
Net income
-$56.42M
EBIT
-$42.07M
EBITDA
-$35.94M
Free cash flow
-$11.87M
Per share
Balance sheet
Liquidity
EPS
-$1.15
EPS diluted
-$1.15
Free cash flow per share
-$0.24
Book value per share
$3.57
Revenue per share
$1.32
TBVPS
$7.25
Total assets
$354.16M
Total liabilities
$178.62M
Debt
$49.82M
Equity
$175.55M
Working capital
$128.98M
Debt to equity
0.28
Current ratio
5.02
Quick ratio
4.91
Net debt/EBITDA
-0.31
Margins
Efficiency
Dividend
EBITDA margin
-55.8%
Gross margin
100%
Net margin
-87.6%
Operating margin
-72.9%
Return on assets
-15.6%
Return on equity
-29.7%
Return on invested capital
-12.3%
Return on capital employed
-13.1%
Return on sales
-65.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TBPH stock price
How has the Theravance Biopharma stock price performed over time
Intraday
-0.09%
1 week
-2.71%
1 month
-3.52%
1 year
7.69%
YTD
-1.47%
QTD
-1.47%
Financial performance
How have Theravance Biopharma's revenue and profit performed over time
Revenue
$64.38M
Gross profit
$64.38M
Operating income
-$46.95M
Net income
-$56.42M
Gross margin
100%
Net margin
-87.6%
Theravance Biopharma's operating margin has increased by 25% YoY but it has decreased by 4.7% QoQ
The operating income is up by 16% YoY but it is down by 7% QoQ
The net income has contracted by 14% from the previous quarter and by 2.2% YoY
TBPH's revenue is up by 12% year-on-year
Growth
What is Theravance Biopharma's growth rate over time
Valuation
What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
2.6
P/S
7.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.3
Theravance Biopharma's EPS has decreased by 15% YoY and by 12% QoQ
TBPH's equity is down by 18% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 13% higher than the last 4 quarters average of 2.3
The P/S is 43% lower than the 5-year quarterly average of 12.3 but 3.5% higher than the last 4 quarters average of 6.8
TBPH's revenue is up by 12% year-on-year
Efficiency
How efficient is Theravance Biopharma business performance
The ROE has contracted by 49% YoY and by 20% from the previous quarter
The company's return on assets fell by 26% YoY and by 16% QoQ
Theravance Biopharma's return on sales has increased by 20% YoY but it has decreased by 8% QoQ
The ROIC has contracted by 13% from the previous quarter but it has grown by 3.1% YoY
Dividends
What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TBPH.
Financial health
How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 98% more than its total liabilities
TBPH's current ratio is down by 7% year-on-year
Theravance Biopharma's total assets has decreased by 7% YoY
Theravance Biopharma's debt is 72% lower than its equity
The debt to equity rose by 22% YoY and by 17% QoQ
TBPH's equity is down by 18% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.